Literature DB >> 18555017

MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1.

Queenie W-L Wong1, Raymond W-M Lung, Priscilla T-Y Law, Paul B-S Lai, Kathy Y-Y Chan, Ka-Fai To, Nathalie Wong.   

Abstract

BACKGROUND & AIMS: Recent studies have emphasized causative links between microRNA (miRNA) deregulations and cancer development. In hepatocellular carcinoma (HCC), information on differentially expressed miRNA remained largely undefined.
METHODS: Array-based miRNA profiling was performed on HCC cells that were derived from chronic carriers of hepatitis B virus (HBV) and hepatitis C virus (HCV), and nonviral-associated patients. Specific microRNA (miR)-223 and miR-222 deregulations were verified in an independent series of tumors. The functional effect of miR-223 was examined further. An integrative analysis of messenger RNA (mRNA) array with in silico predictions defined potential downstream targets of miR-223. A luciferase reporter assay was conducted to confirm target association.
RESULTS: Distinct up-regulations of miR-222, miR-221, and miR-31, and down-regulations of miR-223, miR-126, and miR-122a were identified. Further investigations suggested the highly deregulated miR-223 and miR-222 could unequivocally distinguish HCC from adjacent nontumoral liver, irrespective of viral associations (P <or= .0002). Re-expression of miR-223 in HBV, HCV, and non-HBV non-HCV-related HCC cell lines revealed a consistent inhibitory effect on cell viability (P < .01). Integrative analysis further implicated Stathmin 1 (STMN1) as a downstream target of miR-223. A strong inverse relationship between STMN1 mRNA and miR-223 expressions was shown (P = .006). A substantial reduction in STMN1 protein was further demonstrated upon restoration of miR-223 expression in HCC cell lines. We further showed that miR-223 readily could suppress the luciferase activity in reporter construct containing the STMN1 3' untranslated region (P = .02).
CONCLUSIONS: Our study revealed specific miRNA differential expressions in HCC and underscores the potential importance of miR-223 down-regulations in the development of HCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555017     DOI: 10.1053/j.gastro.2008.04.003

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  197 in total

1.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

2.  Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs.

Authors:  Luisa Novellino; Riccardo L Rossi; Ferruccio Bonino; Daniela Cavallone; Sergio Abrignani; Massimiliano Pagani; Maurizia R Brunetto
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

3.  miR-25 targets TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and promotes apoptosis resistance in cholangiocarcinoma.

Authors:  Nataliya Razumilava; Steve F Bronk; Rory L Smoot; Christian D Fingas; Nathan W Werneburg; Lewis R Roberts; Justin L Mott
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

Review 4.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

5.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

6.  MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.

Authors:  Yong He; Seonghwan Hwang; Yan Cai; Seung-Jin Kim; Mingjiang Xu; Dingcheng Yang; Adrien Guillot; Dechun Feng; Wonhyo Seo; Xin Hou; Bin Gao
Journal:  Hepatology       Date:  2019-06-05       Impact factor: 17.425

7.  MicroRNAs in Cerebral Ischemia.

Authors:  Kai-Ying Lim; Jia-Hui Chua; Jun-Rong Tan; Priyadharshni Swaminathan; Sugunavathi Sepramaniam; Arunmozhiarasi Armugam; Peter Tsun-Hon Wong; Kandiah Jeyaseelan
Journal:  Transl Stroke Res       Date:  2010-12       Impact factor: 6.829

8.  MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1).

Authors:  Defang Sun; Feng Yu; Yutao Ma; Ran Zhao; Xi Chen; Jie Zhu; Chen-Yu Zhang; Jiangning Chen; Junfeng Zhang
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

9.  MicroRNA-9 inhibits vasculogenic mimicry of glioma cell lines by suppressing Stathmin expression.

Authors:  Yuwen Song; Luyan Mu; Xuezhe Han; Qingla Li; Baijing Dong; Hulun Li; Xiaoqian Liu
Journal:  J Neurooncol       Date:  2013-09-17       Impact factor: 4.130

10.  miR-221 overexpression contributes to liver tumorigenesis.

Authors:  Pascal Pineau; Stefano Volinia; Katherine McJunkin; Agnès Marchio; Carlo Battiston; Benoît Terris; Vincenzo Mazzaferro; Scott W Lowe; Carlo M Croce; Anne Dejean
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.